SomaliaTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 7 (5.1–9.3) 67 (48–88)
Mortality (HIV+TB only) 0.44 (0.34–0.56) 4.2 (3.2–5.3)
Prevalence  (includes HIV+TB) 52 (27–85) 491 (254–805)
Incidence  (includes HIV+TB) 29 (25–32) 274 (242–308)
Incidence (HIV+TB only) 2.2 (1.7–2.7) 21 (16–26)
         
Case detection, all forms (%) 45 (40–51)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 5.2 (2.7–7.7) 41 (23–58)
MDR-TB cases among notified pulmonary
TB cases
500 (260–740) 270 (160–390)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 6 248   372
Pulmonary, clinically diagnosed 3 378   70
Extrapulmonary 2 813   22
       
Total new and relapse 12 903    
Previously treated, excluding relapses 227    
Total cases notified 13 130    
Among 12 903 new and relapse cases:
2 783 (22%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 21 (<1%) 200 (29%) 315
Laboratory-confirmed RR-/MDR-TB cases     176
Patients started on MDR-TB treatment ***     76
TB/HIV 2014 Number (%)
TB patients with known HIV status 7 714 (59)
HIV-positive TB patients 248 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 166 (67)
HIV-positive TB patients on antiretroviral therapy (ART) 111 (45)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 226  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (86) 12 994
Previously treated cases, excluding relapse, registered in 2013 (43) 312
HIV-positive TB cases, all types, registered in 2013 (69) 195
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 9
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-26 Data: www.who.int/tb/data